YLL545
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC) . YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth[1].
Product Specifications
CAS Number
1423126-69-5
UNSPSC
12352005
Target
Apoptosis; ERK; STAT; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yll545.html
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(OC3=C4C(NN=C4)=NC=N3)C=C2
Molecular Formula
C19H13F3N6O2
Molecular Weight
414.34
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TGF-beta (1D11.16.8), CF770 conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF405S conjugate, 0.1mg/mL
Mucin 5AC (MUC5AC) (45M1), CF740 conjugate, 0.1mg/mL
